Bicara Therapeutics Inc. BCAX
Updated: 19 Jun 2026
No signal published yet
We already track Bicara Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Bicara Therapeutics Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Bicara Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In May 2026, the company presented three-year follow-up data from a Phase 1/1b study showing deep and durable responses in HPV-negative head and neck cancer. Bicara also completed a $161.8 million public offering in early 2026 to fund operations into 2029. A new randomized dosing study is scheduled to begin in the third quarter of 2026.
What Firelda Watch includes for Bicara Therapeutics Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Bicara Therapeutics Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Bicara Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more